Frontera Therapeutics

Frontera Therapeutics is an emerging, international gene therapy company with a dual focus on innovative rAAV technology and efficient manufacturing. The company has built two proprietary platforms: EXACTE™ for vector design and AAVANCE™ for scalable, low-cost GMP production. Several of its programs, including FT-001 and FT-002, have advanced into Phase II clinical trials with regulatory designations, positioning the company competitively in key therapeutic areas. With R&D in Boston, operations in Shanghai, and manufacturing in Suzhou, Frontera is structured for global development.

Two proprietary platforms: 1) EXACTE™ for rAAV capsid engineering and gene expression cassette optimization. 2) AAVANCE™ for scalable, low-cost GMP production of rAAV using an Sf9 insect cell system, claiming empty capsid levels <1%.

Frontera competes in crowded fields: in ophthalmology against companies like Spark Therapeutics (Roche), Biogen, and others; in cardiology and neurology against large pharma and biotech firms. Its differentiation is predicated on its proprietary capsids and low-cost manufacturing platform.